Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528645 · ClinicalTrials.gov registry record · Phase 2
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00528645: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00528645 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00528645, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.
Interventions
- DRUG saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528645
The ClinicalTrials.gov registry entry for NCT00528645 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which saracatinib is the first listed.
NCT00528645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528645 about?
NCT00528645 is a clinical study titled "AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer". AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.
What is the current status of trial NCT00528645?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2007-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00528645?
The interventions under investigation include: saracatinib (DRUG).
Who is sponsoring clinical trial NCT00528645?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.